Discover. Oncology最新文献

{"title":"Identification and analysis of key transcription factors in esophageal squamous cell carcinoma.","authors":"Zhe-Ran Chen, Zhi-Yuan Cheng, Si-Wei Zhou, Yan-Hui Zhang, Ye Gao, Chu-Ting Yu, Bo Tian, Xun Zhang, Yan Bian, Mei-Juan Hao, Wei Wang, Lei Xin, Han Lin, Luo-Wei Wang","doi":"10.1007/s12672-025-03634-5","DOIUrl":"https://doi.org/10.1007/s12672-025-03634-5","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1810"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disulfidptosis mechanisms and therapeutic implications in cancer metabolic reprogramming and future perspectives.","authors":"Ronghui Chen, Jianhang You, Suxia Weng, Tao Zhao","doi":"10.1007/s12672-025-03538-4","DOIUrl":"https://doi.org/10.1007/s12672-025-03538-4","url":null,"abstract":"<p><p>Regulatory cell death exhibits distinctive advantages in cancer therapy. Among such mechanisms, disulfidptosis effectively inhibits tumor growth by inducing disulfide bond stress and subsequent rupture under particular conditions, thus demonstrating substantial potential for cancer treatment. Genes associated with disulfidptosis contribute to the survival and proliferation of various cancer cell types. They significantly impact the tumor microenvironment (TME) by modulating cancer's metabolic reprogramming and antioxidant response, achieving anti-tumor effects. This review explores the recently identified regulatory cell death mechanism, disulfidptosis, through an examination of its mechanisms, the relationship between relevant genes and cancer, analyses of the TME, and the prospects of emerging therapeutics, offering fresh insights for disulfidptosis research in oncology.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1814"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of LncRNA SNHG3 in human cancers.","authors":"Jinming Tang, Min Su, Yuhang Xiao, Wei Ou, Wenxiang Wang, Ren-Wang Peng, Zhining Wu","doi":"10.1007/s12672-025-03640-7","DOIUrl":"https://doi.org/10.1007/s12672-025-03640-7","url":null,"abstract":"<p><p>An essential category of non-protein-coding RNA molecules, known as long noncoding RNAs (lncRNAs), are naturally occurring RNA sequences exceeding 200 nucleotides in length. Accumulating evidence has unveiled the significant involvement of lncRNAs in various cancers, where they are known to be a key factor for tumors' statement changing, e.g., modulating proliferative, apoptotic, migratory and chemotherapy resistance in cells. In addition, lncRNAs are also regarded as potential diagnostic and prognostic tumor biomarkers. Studies have suggested that lncRNAs modulate biological processes by regulating linear RNA transcription and protein production. A recently discovered long non-coding RNA, SNHG3, is identified to have associations with cancer, which displays atypical expression patterns and functions as an oncogene in various cancers. Additionally, SNHG3 has been demonstrated to hold promise as a diagnostic biomarker and a tool for prognostic assessment in cancer patients. This review summarizes current knowledge about SNHG3's expression, functional roles, molecular mechanisms, and implications for diagnosis and prognosis in human cancers.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1812"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GlycoRNA, a novel RNA modification.","authors":"Binbin Hu, Tianyu Ma, Dongli Zhou, Juan Jiao, Xiangwei Xia","doi":"10.1007/s12672-025-03660-3","DOIUrl":"https://doi.org/10.1007/s12672-025-03660-3","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1809"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort.","authors":"Thuy Thi Thu Pham, Dat Tan Ho, Toan Bao Nguyen, Hai Thanh Phan","doi":"10.1007/s12672-025-03651-4","DOIUrl":"https://doi.org/10.1007/s12672-025-03651-4","url":null,"abstract":"<p><strong>Objective: </strong>Alpha-fetoprotein (AFP), PIVKA-II, and GAAD have been studied effectively for the early diagnosis of hepatocellular carcinoma (HCC), creating an opportunity for effective treatment, thereby improving the survival outcomes. However, evidence was scarce in Vietnam, where patients were largely diagnosed at advanced stages with poor prognosis.</p><p><strong>Methods: </strong>A retrospective study was conducted at a single-center in Vietnam to investigate clinical application of standard cutoffs GAAD (2.57), AFP (20 ng/mL), and PIVKA-II (28.4 ng/mL). Receiver operating characteristic (ROC) analysis and area under the curve (AUC) values were calculated for all markers.</p><p><strong>Results: </strong>Among 2611 participants, there were 128 (4.9%) diagnosed with HCC. In HCC cases, 91.41% were aged ≥ 50 with a male to female ratio of 3.9. There were 58.59% with cirrhosis and 63.28% with hepatitis, dominated by hepatitis B (52.34%). GAAD score attained 98.33% of AUC, sensitivity of 86.7%, and specificity of 98.4%. GAAD was more effective than PIVKA-II and AFP in screening HCC patients. A strategy of combining PIVKA-II and AFP overcame limitations of these two biomarkers used alone, denoted by higher values of sensitivity (84.4%) and specificity (96.0%).</p><p><strong>Conclusion: </strong>This study in Vietnam revealed the performance of GAAD and PIVKA-II plus AFP in the HCC screening strategy. These strategies appeared effective for HCC patients regardless of tumor size (≤ 2 cm) or patient age (≥ 50). Further study is encouraged to confirm these findings.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1813"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlapping risk factors and pathogenic mechanisms in lung cancer and cardiovascular disease.","authors":"Yan Liu, Yifei Li, Haiyang Ning, Yujia Xi, Yifan Li, Jinfeng Ma","doi":"10.1007/s12672-025-03566-0","DOIUrl":"https://doi.org/10.1007/s12672-025-03566-0","url":null,"abstract":"<p><p>Lung cancer and cardiovascular diseases (CVDs) are leading global causes of mortality, with growing evidence suggesting a complex interplay between the two. While traditionally viewed as distinct conditions, shared risk factors and intrinsic mechanisms, particularly inflammation, indicate potential commonalities. This article provides a comprehensive analysis of the roles of endothelial cell activation, the mononuclear phagocyte system, and cytokines in the pathogenesis of both diseases, highlighting the central role of inflammatory pathways. Additionally, we explore the contributions of non-inflammatory factors, such as metabolic dysregulation and coagulation abnormalities, to disease progression. By identifying shared mechanisms, we propose novel preventive and therapeutic targets that could simultaneously address both lung cancer and CVDs. This review aims to deepen the understanding of the intricate relationship between these diseases and provide a foundation for future research and clinical strategies aimed at improving patient outcomes.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1808"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the prognosis of prostate cancer through metabolic pathways.","authors":"Qiang Su, Yi Hu, Bin Dai","doi":"10.1007/s12672-025-03514-y","DOIUrl":"https://doi.org/10.1007/s12672-025-03514-y","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of prostate cancer (PCa) is strongly influenced by metabolism. Thus, we explored candidate genes with metabolism-related functions that can be used to predict PCa prognosis.</p><p><strong>Methods: </strong>To create a training set and two validation sets, RNA data and clinical parameters were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Risk score (RS) was constructed based on metabolism-related gene signatures. The predictive power of the RS was evaluated. A nomogram related to biochemical recurrence-free survival (BCRFS) was built and evaluated. Finally, an enrichment analysis using Gene Set Enrichment Analysis (GSEA) was performed to identify enriched Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) categories. The Human Protein Atlas (HPA) platform was employed to identify the expression of important genes at the protein level.</p><p><strong>Results: </strong>Five gene signatures from 860 metabolism-related genes were selected. RS were constructed using the five-gene signatures, which showed high prognostic power for biochemical recurrence (BCR). The nomogram effectively predicted BCRFS. According to GO analysis, DNA damage is primarily associated with genes involved in metabolism. The five-gene signatures were primarily enriched in sulfur metabolic pathways, as analyzed by KEGG. With the progression of prostate cancer malignancy, the expression of HAGHL, and INPP5E also increased.</p><p><strong>Conclusion: </strong>The study establishes a robust, metabolism-based prognostic model for prostate cancer.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1805"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances of lactylation modification in breast cancer.","authors":"Pu Shen, Meng Yang","doi":"10.1007/s12672-025-03663-0","DOIUrl":"https://doi.org/10.1007/s12672-025-03663-0","url":null,"abstract":"<p><p>Breast cancer (BC), a leading cause of cancer mortality in women, involves complex molecular mechanisms including post-translational modifications (PTMs). While common PTMs are well-studied, lactylation-a novel PTM linking metabolism to epigenetics-has emerged as a critical regulator in BC pathogenesis. The high concentration of lactate caused by the Warburg effect makes lactylation in tumor tissue possible. Machine learning enhances the discovery and analysis of lactylation sites by processing large datasets, revealing patterns that influence tumor behavior and patient outcomes. This review offers a comprehensive analysis of the role of lactylation in breast cancer development and progression. It focuses on the impact on the proliferation, migration, and invasion of breast cancer cells and their association with chemotherapeutic resistance. This review provides valuable insights for the development of targeted therapeutic strategies that may enhance early diagnosis, treatment, and prognostic evaluation of breast cancer. The findings presented here open new avenues for future research and clinical practice.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1811"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA VIM-AS1 is a potential prognostic biomarker and effects on tumor cellular behaviors in breast cancer via impairing miR-29a-3p.","authors":"Yang Yuan, Meng Wei, Linna Kong, Pengfei Li, Huihui Zhang, Wenqing Bian, Qun Yuan","doi":"10.1007/s12672-025-03568-y","DOIUrl":"https://doi.org/10.1007/s12672-025-03568-y","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of our research was to investigate the clinical significance of lncRNA VIM anti-sense 1 (VIM-AS1) and to elucidate its cellular functions in breast cancer patients.</p><p><strong>Methods: </strong>A cohort of one hundred and twenty-one individuals diagnosed with breast cancer and 95 healthy volunteers were recruited for this study. Relative abundances of VIM-AS1 were detected through quantitative real-time polymerase chain reaction (qRT-PCR). Receiver operating characteristic (ROC) was employed for evaluating the diagnosis potential of VIM-AS1. Kaplan-Meier method and Cox regression analysis was performed to further examine the prognostic performance of VIM-AS1. The cellular events of VIM-AS1 were assessed via CCK-8 and Transwell assay. The target interaction of VIM-AS1 and microRNA-29a-3p (miR-29a-3p) was verified via luciferase activity report assays.</p><p><strong>Results: </strong>VIM-AS1 expression was notably elevated in serum of breast cancer, demonstrating a significant diagnostic capacity for breast cancer patients. Its abnormal expression level was significantly correlated with TNM (tumor node metastasis, P = 0.020) and lymph node metastasis (P = 0.040). Moreover, a reduced overall survival rate was observed in patients exhibiting high VIM-AS1 expression (P = 0.001). Multivariate analysis illustrated that VIM-AS1 (P = 0.003, HR = 2.345, 95%CI = 1.340-4.103) was an independent prognostic biomarker for breast cancer patients, alongside TNM (P = 0.006; HR = 2.251; 95%CI = 1.24-4.009). Functionally, silencing VIM-AS1 resulted in the inhibition of key cell behaviors in vitro, including proliferation, migration and invasion. Besides, VIM-AS1 was found to negatively regulated miR-29a-3p, which may relieve the impacts of VIM-AS1 on breast cancer cells.</p><p><strong>Conclusion: </strong>VIM-AS1 exhibited aberrant expression in breast cancer, playing a critical role in tumor development by targeting miR-29a-3p. Our findings highlight the potential of VIM-AS1 as a novel diagnostic and prognostic biomarker in breast cancer. However, further in vivo studies and exploration of miR-29a-3p downstream targets are needed to fully elucidate the mechanistic role of VIM-AS1 in breast cancer progression.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1807"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of pyroptosis in ovarian cancer.","authors":"Yingzhi Zhou, Tian Peng, Jiahan Zhang, Ruojia Liang","doi":"10.1007/s12672-025-03518-8","DOIUrl":"https://doi.org/10.1007/s12672-025-03518-8","url":null,"abstract":"<p><p>Pyroptosis is a novel form of programmed cell death that depends on gasdermin-mediated pore formation in the plasma membrane and the release of inflammatory factors. Pyroptosis is closely linked to the occurrence and progression of almost all types of cancer, including ovarian cancer, which is the seventh most common malignancy among women worldwide and poses a significant threat to women's health. Research indicates that pyroptosis may offer potential strategies for monitoring and treating ovarian cancer. This review systematically discusses the molecular mechanisms of pyroptosis and its role in the onset, progression, prognosis, and treatment of ovarian cancer, providing deep insights for further research in this field.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1806"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}